CD38 and acute myeloid leukemia: Previous studies have demonstrated that CD34+/CD38- (hematopoietic stem cell/hematopoietic progenitor surface markers) patients with AML were refractory and patients with CD34+/CD38+ AML had a good prognosis 41-43.